Form 4: Bio-Rad Laboratories Executive Acquires Stock Options
SEC Form 4 Filing
Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, acquired 2,918 non-qualified stock options on March 3, 2025.
Summary
- Sedat Evran, an EVP at Bio-Rad Laboratories, filed a Form 4 indicating a change in beneficial ownership.
- On March 3, 2025, Evran acquired 2,918 non-qualified stock options with an exercise price of $256.45.
- These options vest over four years, at a rate of 25% per year on the anniversary of the grant date.
- The options expire on March 3, 2035.
- Following the transaction, Evran directly owns 2,918 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future performance.
Stakeholder Impact
- Shareholders may view insider transactions as a signal of management's confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of earliest transaction: acquisition of stock options. |
| 03/03/2025 | Grant date of the non-qualified stock options. |
| 03/05/2025 | Date of signature for the Form 4 filing. |
| 03/03/2035 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.